Multidisciplinary Insights to Enhance Biomarker Testing Practices in Non-Small Cell Lung Cancer

This webinar is part 3 in a 3-part curriculum.

Program Description

The management of non-small cell lung cancer (NSCLC) has evolved significantly with the integration of precision medicine. This approach allows for the selection of therapies based on a patient's specific tumor characteristics, which can lead to improved survival outcomes and greater treatment efficacy. For oncology pharmacists, being knowledgeable about this topic is crucial, as they play a central role in interpreting these test results and applying them to treatment and management decisions. This 3-part continuing education program, "Precision in Practice for Oncology Pharmacists: Exploring Opportunities to Ensure Accuracy in Non-Small Cell Lung Cancer Treatment," is designed to equip oncology pharmacists with the knowledge and skills necessary to navigate this evolving field and play a central role in delivering precision care in NSCLC. The series consists of 2 webinars and a multidisciplinary panel discussion exploring the current state of precision medicine in NSCLC, detailing its methodologies, clinical applications, and practical implementation for oncology pharmacists. Explore each of these activities to advance your knowledge and skills in precision medicine for NSCLC, and learn how to apply these concepts to improve patient care within your own practice.

Target Audience: Oncology Pharmacist

Type of Activity: Application
Release date: November 10, 2025
Expiration date: November 10, 2026
Learner level: Intermediate
Time to complete activity: 1.0 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Document the unique and shared barriers to optimal biomarker testing across academic institutions and community-based environments
• Identify pharmacist-led interventions to improve biomarker testing practices in non-small cell lung cancer
• Exercise best practices that have optimized biomarker testing workflows in NSCLC

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.10 CEU) under the ACPE universal activity number 0290-0000-25-369-H01-P. The activity is available for CE credit through November 10, 2026.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures:

Stefanie Houseknecht, PharmD, BCOP, has the following relevant financial relationships with ineligible companies to disclose: Consultant: AstraZeneca; Advisory Board: Daiichi-Sankyo; Stock: Pfizer.

Alia C. Lynch, PharmD, BCOP, has the following relevant financial relationship with an ineligible company to disclose: Advisory Board: Daiichi-Sankyo.

Mya Tran, PharmD, BCOP, has the following relevant financial relationship with an ineligible company to disclose: Advisory Board: Johnson & Johnson.

Pharmacy Times Continuing Education™ Planning Staff: Jim Palatine, RPh, MBA; Amy L. Morris, PharmD, BCOP; Crissy Wilson; Victoria Chirdo; Susan Pordon; Brianna Winters; and Chloe Taccetta have no financial relationships with ineligible companies to disclosePharmacy Times® Editorial Staff— Aislinn Antrim

Any relevant financial relationships listed for these individuals have been mitigated.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer

CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms